✦ LIBER ✦

Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma

✍ Scribed by Tadeusz Robak; Piotr Smolewski; Barbara Cebula; Anna Szmigielska-Kaplon; Krzysztof Chojnowski; Jerzy Z. Blonski

Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 187 KB
Volume: 107
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.22196

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized comparison of cladribine alon

Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low-grade B-cell non-Hodgkin lymphoma patients : Final report of the Polish Lymphoma Research Group

✍ Ewa Kalinka-Warzocha; Jaroslaw Wajs; Ewa Lech-Maranda; Bernadetta Ceglarek; Jerz 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 190 KB 👁 2 views

Phase 2 trial of rituximab and bortezomi

Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma

✍ Robert A. Baiocchi; Lapo Alinari; Mark E. Lustberg; Thomas S. Lin; Pierluigi Por 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 257 KB 👁 1 views

Long-term results of the treatment of pa

Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group

✍ David J. Inwards; Paul A. S. Fishkin; David W. Hillman; David W. Brown; Stephen 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB 👁 1 views

## Abstract ## BACKGROUND. The objective of this study was to test cladribine (2‐CDA) alone and in combination with rituximab in patients with mantle cell lymphoma (MCL). ## METHODS. Patients with MCL were treated on 2 sequential trials. In Trial 95‐80‐53, patients received 2‐CDA as initial ther

Liposome-encapsulated doxorubicin in com

Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines

✍ Luigi Rigacci; Silvia Mappa; Luca Nassi; Renato Alterini; Valentina Carrai; Fran 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 155 KB

## Abstract ## Background To assess the efficacy and safety of the combination of non‐pegylated liposome‐encapsulated doxorubicin (Myocet®) with cyclophosphamide, vincristine, prednisone and rituximab (R‐COMP) in patients with aggressive non‐Hodgkin's B‐cell lymphomas. ## Methods Twenty‐one pati

Proliferation predicts failure-free surv

Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine

✍ Mar Garcia; Jorge E. Romaguera; Kedar V. Inamdar; George Z. Rassidakis; L. Jeffr 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 393 KB 👁 1 views

A pilot study of epratuzumab and rituxim

A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma

✍ Ivana N. M. Micallef; Brad S. Kahl; Matthew J. Maurer; Ahmet Dogan; Stephen M. A 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB 👁 2 views